Pulmonary Embolus (PE)
Domino Effect: Pulmonary Emboli (PE)
Pulmonary embolus (PE) is one of those diagnoses that can look deceptively ordinary until it tips into catastrophe. A patient may present with nothing more than shortness of breath or vague chest discomfort, and within minutes, spiral into syncope, obstructive shock, or cardiac arrest.
What makes PE uniquely dangerous is that it hijacks two essential systems at once: gas exchange and hemodynamics. The clot doesn’t just block blood—it rewrites the physics of breathing and circulation in real time.
Blockage Forms
A thrombus, usually originated deep in the veins of the legs or pelvis, dislodges and travels through the right heart into the pulmonary arteries.
This sudden obstruction immediately strips portions of the lung of their blood supply. Air still enters those alveoli, but there’s no blood to pick up oxygen or offload CO₂. This creates dead space ventilation, where effort is wasted and efficiency plummets [5,6].
RV Strain
Unlike the left ventricle, the RV is not built to pump against high resistance.
- A large or central PE spikes pulmonary vascular resistance (PVR) in seconds.
- The RV dilates, stretches its free wall, and bows the interventricular septum into the LV cavity.
- Stroke volume falls, systemic pressure drops, and coronary perfusion of the RV itself falters.
This vicious cycle—RV dilation, septal shift, falling LV preload, worsening hypotension—can spiral into obstructive shock [7].
Cardiopulmonary Collapse
With perfusion impaired, tissue oxygen delivery plunges.
Meanwhile, gas exchange becomes progressively abnormal:
- EtCO₂ falls (reflecting increased dead space)
- PaO₂ drops, and lactate rises
If no intervention occurs, the RV succumbs, the LV is starved of preload, and pulseless electrical activity (PEA) arrest follows [1,7].
—————————————————————
The timeline is what makes PE so unforgiving. In a high-risk presentation, mortality can occur within hours, often before imaging can even be obtained. That is why early recognition, supportive measures that protect the RV, and rapid initiation of anticoagulation or reperfusion therapy are cornerstones of survival [1,2,7].
From a nursing perspective, management of PE is not just about memorizing drug doses or algorithms—it’s about seeing the physiologic dominoes fall before the patient crumbles. Understanding why EtCO₂ drops, why fluids can hurt instead of help, and why early lysis saves the RV gives bedside providers the ability to anticipate and act decisively.
Epidemiology
Pulmonary embolus is common enough to be on every differential, but dangerous enough that missing it can be catastrophic.
In the United States alone, it’s estimated that nearly 400,000 people develop symptomatic PE each year, and more than 100,000 deaths annually are attributed to acute pulmonary embolism [6].
That makes PE one of the leading causes of sudden cardiovascular death, rivaling myocardial infarction and stroke.
Timing Matters
Half of PE-related deaths occur within the first two hours of presentation [6].
That means the difference between survival and catastrophe often hinges on early recognition by nurses at the bedside.
Patients who survive the initial event but are inadequately treated remain at risk for recurrent PE, right ventricular failure, or chronic complications like CTEPH (chronic thromboembolic pulmonary hypertension).
Risk Factors
Risk factors align with Virchow’s triad—venous stasis, endothelial injury, and hypercoagulability. Practical examples:
Stasis:
- Prolonged bedrest
- Obesity
- Heart failure
- Stroke
- Long travel times
Endothelial injury:
- Recent surgery
- Trauma
- Central venous lines
Hypercoagulability:
- Cancer
- Pregnancy
- Estrogen therapy
- Inherited thrombophilias
ICU patients frequently combine all three. Consider a ventilated patient after trauma: immobile, central lines, multiple transfusions, maybe on pressors—each factor layers risk on top of risk.
Disparities and Demographics
PE incidence increases with age, but younger patients are not immune.
Importantly, there are racial and sex disparities: some studies suggest higher incidence and worse outcomes in Black patients, and women have increased risk during reproductive years due to estrogen exposure [6].
Pathophysiology
PE is unique because it doesn’t just obstruct blood flow; it rewrites both ventilation–perfusion (V/Q) matching and circulatory mechanics at the same time.
From Embolus to V/Q Mismatch
When a clot lodges in the pulmonary arteries, it instantly cuts off blood flow to regions of lung that remain well-ventilated. Air still enters the alveoli, but oxygen molecules have no red blood cells waiting at the capillaries. This creates dead space ventilation—ventilation without perfusion.
Early gas exchange changes:
The patient’s PaO₂ begins to fall because less blood is participating in oxygen uptake. Meanwhile, PaCO₂ may look deceptively normal, because the patient compensates with tachypnea and high minute ventilation.
EtCO₂ clue:
Because exhaled CO₂ reflects perfused alveoli, and many alveoli are no longer perfused, EtCO₂ drops disproportionately compared to PaCO₂. The widened PaCO₂–EtCO₂ gap is a red flag for dead space [5,6].
Later changes:
Over time, inflammation and reduced surfactant downstream cause alveolar collapse and small pulmonary infarctions. These regions behave more like shunt physiology (perfusion without ventilation), layering hypoxemia on top of dead space [6].
Takeaway: A PE patient can look deceptively “normal” on PaCO₂ early, while their EtCO₂ is already plummeting. This mismatch is one of the earliest physiologic footprints of PE.
—————————————————————
Pulmonary Vascular Resistance (PVR) and RV Afterload
The clot doesn’t just steal oxygen exchange; it also spikes resistance in the pulmonary circuit. The right ventricle (RV) is built for low-pressure pumping into a compliant pulmonary bed. It can handle gradual increases (like in chronic lung disease), but it is not designed to face a sudden wall of resistance.
RV dilation:
Acute obstruction increases PVR → RV cavity dilates to maintain stroke volume.
Septal shift:
As RV pressure rises, the interventricular septum bows into the LV cavity, impairing LV filling. Stroke volume falls, and systemic blood pressure drops [7].
Coronary mismatch:
The RV depends on perfusion during both systole and diastole, but hypotension reduces its own coronary blood supply. RV ischemia develops, further weakening contractility, and the vicious cycle accelerates.
This is why in massive PE, patients can suddenly collapse into obstructive shock or pulseless electrical activity (PEA) arrest: the RV fails acutely, the LV is starved of preload, and forward flow ceases [1,7].
—————————————————————
Neurohormonal and Inflammatory Amplifiers
PE also triggers a neurohormonal surge:
- Catecholamine release drives tachycardia to preserve cardiac output.
- Endothelin and thromboxane are released locally, causing reflex pulmonary vasoconstriction, further amplifying PVR [6].
- Systemic inflammation can worsen endothelial permeability, promoting edema and secondary atelectasis.
The end result is a storm of mechanical obstruction, vasoconstriction, and RV strain, all happening within minutes.
—————————————————————
Linking Physiology to Clinical Presentation
Syncope: When the RV can’t sustain forward flow, cerebral perfusion falters — explaining why syncope can be a presenting symptom even without hypoxemia.
Hypoxemia with hypocapnia: Tachypnea keeps PaCO₂ low at first, while PaO₂ continues to fall.
Sudden PEA arrest: Not due to electrical instability, but because the RV–LV preload pipeline collapses under acute afterload.
—————————————————————
Why Pathophysiology Matters
Understanding this cascade explains why our therapies look the way they do.
Small cautious fluid bolus?
To improve preload without stretching the RV wall.
Norepinephrine first?
To maintain systemic pressure and thus RV coronary perfusion.
Early reperfusion (tPA/TNK)?
To relieve the RV of impossible afterload before it spirals into ischemic failure.
Clinical Presentation
One of the challenges with PE is that it rarely announces itself with a single, classic picture. Instead, it hides inside symptoms we see every day in the ICU: shortness of breath, chest pain, tachycardia. What makes PE deadly is not just its frequency, but its deceptively varied presentation. The key for nurses is to see the patterns beneath the noise.
Common Symptoms and Their Physiology
Dyspnea (~70%): The most frequent complaint. It reflects both wasted ventilation (dead space) and impaired oxygen delivery to tissues [5].
Pleuritic chest pain (~60%): Caused by irritation of the pleura overlying small pulmonary infarcts, or by strain on the pulmonary vasculature [5].
Cough (~35%) and hemoptysis (~10%): More likely when smaller peripheral clots infarct lung parenchyma [5].
Syncope (≤10%): A red-flag symptom. In PE, syncope usually indicates large central clot burden causing acute RV failure and transient cerebral hypoperfusion [5,7].
Takeaway: A PE can masquerade as pneumonia, COPD, asthma, or anxiety. But when symptoms are sudden, severe, or don’t line up with exam findings, suspicion should rise.
—————————————————————
Bedside Signs
Tachypnea (~50%): Often the earliest objective finding. A patient with sudden tachypnea, especially without clear pneumonia or fluid overload, deserves PE consideration [5].
Tachycardia (~25%): Driven by catecholamine surge and RV strain. Persistent sinus tachycardia out of proportion to fever or anemia should be taken seriously [5].
Leg findings (~40–45%): Calf pain, swelling, or tenderness suggest proximal DVT, the most common source of PE [5,6].
JVD or loud P2 (~10–15%): Subtle signs of pulmonary hypertension and RV pressure overload in more severe cases [7].
Hypotension/shock (~5%): A late but ominous finding, usually signaling massive PE with impending collapse [1].
—————————————————————
Clinical Phenotypes by Risk Category
Understanding how PE presents across the risk spectrum helps tailor both suspicion and urgency.
Massive (high-risk) PE:
- Features: Hypotension (SBP <90 mmHg for >15 min), shock, or cardiac arrest.
- Presentation: Pale, diaphoretic, tachycardic, hypotensive, with distended neck veins. Often the patient collapses abruptly (syncope, PEA arrest).
Mortality is high if reperfusion is delayed [1].
Submassive (intermediate-risk) PE:
- Features: Normotensive but evidence of RV dysfunction (echo RV dilation, McConnell sign) and/or biomarker elevation (troponin, BNP).
- Presentation: Dyspnea, tachypnea, mild hypoxemia, maybe borderline blood pressure. These patients can look stable but deteriorate rapidly if not closely monitored [4,7].
Low-risk PE:
- Features: Normotensive, no RV dysfunction, no biomarker elevation.
- Presentation: Stable vitals, may have only pleuritic pain, cough, or incidental hypoxemia. These patients often do well with anticoagulation alone [2,7].
—————————————————————
Subtle Clues
Unexplained new hypoxemia: A ventilated patient suddenly requires higher FiO₂ without obvious pneumonia or edema.
EtCO₂ drop despite constant minute ventilation: Suggests new dead space ventilation.
PEA arrest with clean lungs and no tamponade: Always consider massive PE as the cause.
Diagnostic Strategy
PE diagnosis is a balance between pretest probability, time to harm, and test characteristics. Our role is to shorten the path from suspicion → treatment without over-imaging or delaying life-saving therapy.
—————————————————————
Start with pretest probability
Use a validated clinical probability assessment (Wells or Geneva Scale) to decide whether you’re in a rule-out or rule-in lane. In practice this means:
- Low/Intermediate probability: D-dimer can exclude PE if negative.
- High probability: Skip D-dimer → imaging (or treat first if unstable).
Clues that increase probability:
- Sudden unexplained tachypnea
- Syncope
- Pleuritic pain
- Leg DVT signs
- An EtCO₂ drop out of proportion to PaCO₂ (dead space physiology) [5,6].
Probability tools guide testing; they don’t replace judgment. If your patient is crashing, move straight to echo-supported treatment while arranging definitive imaging [1,5].
—————————————————————
D-Dimer
What it is: a fibrin degradation product; sensitive for clot turnover but not specific.
Who it helps: In low/intermediate probability patients, a negative test can exclude PE and prevent imaging [5].
Age-adjusted threshold: Above age 50, many pathways accept age × 10 ng/mL (FEU) as the negative cut-off to improve specificity in older patients [5].
Caveats: Post-op, pregnant, cancer, infection, and ICU patients often have elevated baseline D-dimer; use with caution and lean on imaging sooner in these groups [5,6].
—————————————————————
ABG & Capnography
ABG: Hypoxemia with a widened A–a gradient is common; PaCO₂ may be normal/low early (tachypnea) and rises late with fatigue [5,6].
EtCO₂: Often falls relative to PaCO₂ due to increased dead space; a widening PaCO₂–EtCO₂ gap should raise suspicion, especially when vitals are “too tachypneic for the story” [5,6].
Great for trend and pretest probability—not diagnostic in isolation.
—————————————————————
Imaging Choices
CT Pulmonary Angiogram (CTPA)-First-line in most adults
Pros: Fast, high diagnostic accuracy, shows clot location and RV/LV ratio, and often reveals alternative diagnoses [5].
Cons: Iodinated contrast (renal allergy/AKI risk), radiation.
Best Used: Hemodynamically stable patients with positive D-dimer or high clinical probability [5].
—————————————————————————————————————
V/Q Scan-When CTPA isn’t feasible
Pros: No iodinated contrast; useful with contrast allergy or renal impairment.
Interpreting: A high-probability scan in the right pretest context is diagnostic; nondiagnostic scans push you back to alternate testing [5].
—————————————————————————————————————
Compression Ultrasound of the Legs
Why: If proximal DVT is found in a patient with suspected PE, you have actionable information and can treat, especially if chest imaging must wait [5,6].
—————————————————————————————————————
Bedside Echocardiography- When the Patient is too Unstable to Transport to CT
Role: In shock or arrest, echo signs of acute RV strain (dilation, septal D-shape, RV/LV > ~1) can justify presumptive reperfusion when imaging is unsafe or delayed [1].
Note: Echo does not “rule out” PE in stable patients; it’s a risk and resuscitation tool [1,7].
—————————————————————————————————————
Chest radiograph
Often normal or nonspecific in PE; useful to exclude alternative causes of hypoxemia or chest pain (pneumonia, pneumothorax) [5].
—————————————————————
Labs and ECG
Troponin/BNP: Elevations imply RV myocardial injury/strain and help risk-stratify (intermediate- vs high-risk), but do not diagnose PE [7].
ECG: Sinus tachycardia is most common; S1Q3T3, RBBB, or right axis deviation may appear in larger emboli— but only suggestive of PE, not diagnostic [5].
—————————————————————
Diagnosis Decision Tree
Initial Resuscitation
Stabilize the RV & Protect Perfusion
When PE patients crash, the reflex is often to treat them like septic shock: fluids and pressors. But PE physiology demands a different playbook. The central problem isn’t vasodilation or hypovolemia—it’s RV afterload overload. The goal is to support oxygenation and perfusion while buying time for reperfusion therapy.
First steps: airway, oxygen, monitoring
Airway/O₂: Give supplemental oxygen to keep SpO₂ >90%. Avoid unnecessary intubation—positive pressure ventilation increases intrathoracic pressure, which can collapse RV preload and trigger arrest [7]. If you must intubate, pre-oxygenate generously and use hemodynamically gentle induction agents.
Monitoring: Place on continuous ECG, SpO₂, and EtCO₂. Watch trends: a sudden EtCO₂ drop during resuscitation may herald worsening RV output or PEA arrest [5].
IV access: Get two large-bore lines (or central access if feasible). These patients often need thrombolytics or vasopressors on short notice [1].
—————————————————————
Circulation: fluids and pressors (RV-specific strategy)
Fluids: The RV is already dilated and struggling. Too much fluid worsens septal shift and lowers LV preload. Small boluses (≤500 mL) may be cautiously trialed if the patient is volume-depleted, but avoid aggressive fluid resuscitation [7].
Pressors:
- Norepinephrine is first-line—maintains systemic perfusion pressure and RV coronary perfusion.
- Vasopressin can be added for synergistic support without raising PVR.
Inotropes: If shock persists despite adequate MAP, dobutamine or milrinone can augment RV contractility, but risk systemic hypotension; combine with norepinephrine if used [7].
—————————————————————
Rhythm and Arrest: ACLS with PE lens
If the patient arrests, the ACLS algorithm applies—but PE is one of the few reversible causes where you must treat the cause immediately.
- Expect PEA arrest (organized rhythm, no pulse).
- High-quality CPR remains the bridge, but ROSC often won’t return without clot relief.
- If PE is strongly suspected, give systemic thrombolysis during the code (alteplase 50 mg IV bolus or TNK single weight-based bolus) [1,4].
- Monitor EtCO₂ during compressions; a sudden rise may be your first marker of ROSC [5].
—————————————————————
Empiric Anticoagulation
Unless contraindicated, start unfractionated heparin (UFH) infusion as soon as PE is suspected in the unstable patient.
UFH is preferred over LMWH or direct oral anticoagulants (DOACs) because it can be stopped quickly if thrombolysis or catheter intervention is pursued [3].
—————————————————————
Escalation pathways
High-risk/unstable PE:
Move toward reperfusion therapy—systemic lysis, catheter-directed therapy, or surgical embolectomy depending on resources and contraindications [1].
If Peri-Arrest:
Immediate systemic lysis is recommended unless absolute contraindications exist. If contraindications, activate surgical or catheter teams early [4].
ECMO (if available):
Consider veno-arterial ECMO as a bridge to reperfusion in refractory shock or arrest when lytics are contraindicated [7].
—————————————————————
Nursing Pearls
Fluids are not benign—a liter too much can push the RV into failure.
Norepi first, not dopamine—because RV ischemia worsens with hypotension.
Avoid unnecessary intubation—positive pressure can tip the balance from tenuous to code.
Suspect PE in PEA arrest when CPR “feels good” (compressions with recoil) but EtCO₂ stays very low—classic for massive obstruction.
Anticoagulation
The Foundation of Therapy
No matter the size of the clot, anticoagulation is the backbone of PE management. Even if reperfusion is needed, anticoagulation keeps new thrombus from forming while the body (or the thrombolytic) clears the existing obstruction. Delays in starting anticoagulation directly increase the risk of recurrent embolism and death [3,7].
Mechanism of action: stopping the cascade
When a thrombus forms, thrombin (factor IIa) and factor Xa are the engines of clot propagation. Anticoagulants target these:
Heparins (UFH/LMWH): Bind to antithrombin and accelerate its inhibition of Xa and IIa. This halts the assembly line that keeps the clot growing.
DOACs (direct oral anticoagulants): Either directly block Xa (apixaban, rivaroxaban, edoxaban) or IIa (dabigatran). They slam the brakes on thrombin activity without needing antithrombin as a middleman.
Fondaparinux: Synthetic pentasaccharide that selectively enhances antithrombin’s inhibition of Xa.
Direct thrombin inhibitors (argatroban, bivalirudin): Used in heparin-induced thrombocytopenia (HIT) because they bypass the heparin–antithrombin axis [3].
Anticoagulants don’t dissolve existing clot, but they freeze the clotting cascade in place, allowing endogenous fibrinolysis to do the cleanup.
—————————————————————
Why Timing Matters
The initiation phase (first 10 days after diagnosis) carries the highest risk of recurrence and death. Starting anticoagulation promptly—even before confirmatory imaging in high-suspicion cases—is guideline-supported when bleeding risk is acceptable [2,3].
—————————————————————
Agent Selection: Choosing Wisely at the Bedside
The right drug depends on clinical stability, renal/hepatic function, bleeding risk, and likelihood of reperfusion therapy.
Unfractionated Heparin (UFH):
Best for unstable PE or when thrombolysis, CDT, or surgery are being considered.
- Advantage: short half-life, rapidly reversible, can be stopped quickly if bleeding or procedures occur.
- Monitoring: aPTT or anti-Xa.
- Use when CrCl <30 mL/min or severe renal impairment.
- Downside: requires IV infusion and frequent monitoring [2,3].
Low-Molecular-Weight Heparin (LMWH; e.g., enoxaparin):
- Preferred in most stable patients with normal renal function.
- Predictable dosing, no routine monitoring.
- Lower risk of HIT compared with UFH.
- Limitation: renally cleared; dose adjustments or avoidance in advanced CKD [3].
DOACs (apixaban, rivaroxaban, edoxaban, dabigatran):
- Increasingly favored for long-term therapy.
- Apixaban & rivaroxaban: can start immediately (no heparin lead-in).
- Dabigatran & edoxaban: require ≥5 days of parenteral anticoagulation before starting.
- Advantages: oral, predictable PK, fewer dietary/drug interactions than warfarin.
- Limitations: caution in pregnancy, cancer (varies by institution), or severe renal/hepatic disease [3].
Fondaparinux:
- Useful in patients with history of HIT or those who need once-daily dosing.
- Avoid in severe renal impairment [3].
Direct thrombin inhibitors (argatroban, bivalirudin):
- Reserved for active HIT or when both heparin and LMWH are contraindicated [3].
—————————————————————
Anticoagulation in Special Contexts
Cancer: LMWH historically first-line; DOACs now acceptable in many cases but may increase bleeding risk in GI/GU malignancies.
Pregnancy: LMWH preferred; DOACs contraindicated.
Renal failure: UFH is safest.
Massive PE requiring thrombolysis: Start with UFH—easy to pause around lysis or catheter-directed intervention [1,3].
—————————————————————
Pearls & Pitfalls
Don’t delay initiation. Anticoagulation should be started as soon as PE is suspected and bleeding risk is acceptable—even before imaging in unstable or high-probability cases [2,3].
UFH is your friend when lysis is on the table. Short half-life makes it safest around procedures [1].
DOACs simplify the long game. Once stable, transitioning patients to DOACs can reduce hospital length of stay and bleeding complications [3].
Monitor renal function. Many anticoagulants are renally cleared—avoid surprises with accumulating drug.
Reperfusion Therapy
Goal: drop pulmonary vascular resistance (PVR) fast enough to abort the RV afterload spiral. Timing matters because mortality clusters early in high-risk PE [7].
Who gets reperfusion?
High-risk (massive) PE: hypotension/shock or cardiac arrest attributable to PE → reperfusion now, unless an absolute contraindication exists—and in arrest many “absolute” contraindications become relative given lethality of PE [1,4].
Intermediate-high risk: normotensive with both RV dysfunction and positive biomarkers. Not routine lysis, but consider if clinical trajectory worsens despite anticoagulation and optimized support (rising O₂/pressors, syncope, lactate, clot-in-transit) and bleeding risk is acceptable; involve PERT early [4,7].
Intermediate-low / Low risk: reperfusion generally not indicated; anticoagulation alone [2,7].
Reperfusion is most indicated when the RV is losing despite your best supportive moves, or when it’s already lost (shock/arrest).
Which Approach Should We Use
Systemic fibrinolysis (tPA or TNK): fastest to deploy everywhere; best for time-critical high-risk PE when bleeding risk is acceptable or when CDT/surgery aren’t immediately available [1,4].
Catheter-directed therapy (CDT): consider when bleeding risk makes systemic lysis unsafe, when systemic lysis fails, or when local anatomy/operator expertise favors targeted debulking (with or without low-dose lytic) [4].
Surgical embolectomy: for failed lysis, contraindications to lysis, or large central clot with rapid deterioration in centers with cardiothoracic capability; may reduce recurrent PE after failed lysis vs repeating lysis (evidence limited; center experience rules) [4].
VA-ECMO (bridge): in select cases, as a bridge to CDT/surgery for refractory shock/arrest or when lytics are contraindicated [1,7].
Airway & Ventilation Considerations in Massive PE
The airway in massive PE is precarious. Positive pressure can worsen RV preload, raise PVR, and tip a tenuous patient into PEA.
Your aim is simple: oxygenate without sabotaging RV perfusion—and if intubation is unavoidable, cross the bridge with pressors already up and ventilator settings that don’t punish the RV [1,7].
Priorities Before Intubation: Optimize Physiology First
Oxygenation goal: SpO₂ ≥90% (PaO₂ ~60–80) using nasal cannula → NRB → HFNC; add gentle NIV only if it clearly improves oxygenation and work of breathing without causing hypotension [7].
Perfusion pressure: Start norepinephrine early; target MAP ≥65–70 mmHg to preserve RV coronary perfusion. Consider vasopressin as an adjunct if needed [7].
EtCO₂: Falling EtCO₂ despite effort suggests rising dead space/low forward flow—escalate support and call the team [5].
Bedside Considerations for Intubation
Pre-induction stabilization:
- Norepinephrine running before induction; have push-dose ready.
- Volume: only a small test bolus (≤250–500 mL) if clearly preload-responsive; avoid routine liters [7].
Induction choices:
- Etomidate (0.2–0.3 mg/kg) or ketamine (~1 mg/kg) for blood-pressure stability.
- Avoid big propofol boluses (vasodilation → RV ischemia).
- Rocuronium for rapid control.
Apneic oxygenation:
HFNC or nasal cannula left in place to reduce desaturation.
Avoid aggressive BVM:
If you must bag, use low inspiratory pressures, slow rate, and minimal PEEP to prevent sudden RV afterload/preload hits [7].
CTEPH (chronic thromboembolic pulmonary hypertension)
What it is:
After an acute PE, a minority of patients don’t fully clear thrombus. Instead, organized, fibrotic clot adheres to the pulmonary arterial intima and remodels the vascular bed. The result is fixed mechanical obstruction plus secondary small-vessel disease → persistently elevated pulmonary vascular resistance (PVR), progressive RV afterload, and exertional limitation. This is CTEPH—a treatable and sometimes curable cause of pulmonary hypertension when recognized early [6,7].
Why some patients develop CTEPH
Unresolved thrombus → scar:
Fibrin organizes, endothelialization traps it against the vessel wall, forming “webs,” bands, and pouch lesions that don’t respond to standard anticoagulation.
Microvascular remodeling:
Distal arteriopathy (muscularization, intimal thickening) develops downstream of chronic obstruction, amplifying PVR beyond what the visible clot explains.
RV Strain:
Persistent afterload stretches the RV, flattens the septum, and gradually limits stroke volume—patients report dyspnea on exertion long after the index PE [6,7].
Who and When to Suspect
Timepoint:
Symptoms that persist or recur beyond ~3 months after a PE despite therapeutic anticoagulation deserve a CTEPH screen.
Symptoms/Signs:
Exertional dyspnea, exercise intolerance, fatigue, near-syncope/syncope on exertion, edema, loud P2/JVD, or new murmurs of TR.
Risk backdrop:
Recurrent/large central PE, delayed diagnosis, chronic inflammatory states, or splenectomy can raise suspicion—but anyone with unexplained post-PE limitation is a candidate for evaluation [6,7].
Possible Treatment Options:
- Anticoagulation (lifelong)
- Pulmonary Endarterectomy
- Balloon Pulmonary Angioplasty
- Medical Therapy: pulmonary vasodilators
Contact Us
Help up improve the Crit Bit Corner. Follow the link below to help us improve the newsletter or suggest future Crit Bit topics!
References
- Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults. UpToDate Pathway 120061; Aug 11, 2025.
- Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults. UpToDate Pathway 120060; Aug 11, 2025.
- Lip GYH, Stevens SM. Venous thromboembolism: Initiation of anticoagulation. UpToDate; May 7, 2025 (lit review through Aug 2025).
- Rivera-Lebron B, Weinberg AS. Acute PE: Reperfusion therapy in intermediate- and high-risk patients. UpToDate; Jun 17, 2025 (lit review through Aug 2025).
- Thompson BT, Kabrhel C, et al. Clinical presentation and diagnostic evaluation of suspected PE. UpToDate; Aug 25, 2025.
- Thompson BT, Kabrhel C. PE: Epidemiology and pathogenesis in adults. UpToDate; Apr 25, 2025.
- Weinberg AS, Rali P. Acute PE: Treatment overview and prognosis. UpToDate; Jul 14, 2025.
Credits:
Created with images by Yauhen - "X-ray image showing lungs with significant interstitial markings." • Sergey Nivens - "Laboratory test" • Vector Market - "Male lung cancer biopsy respiratory system in x-ray. 3d render " • Mrammon - "A doctor is holding a stethoscope and a lung model" • Richman Photo - "x-ray of chest show cavity at right lung and interstitial infiltrate both lung due to TB infection" • mi_viri - "Pulmonologist doctor, lungs specialist. Aesthetic handdrawn highlighted illustration of human lings. Neutral grey background, studio photo and collage." • greenbutterfly - "Radiology Doctor working diagnose treatment virtual Human Lungs and long Covid 19 on modern interface screen.Healthcare and medicine,Innovation and Medical technology Concept." • stockdevil - "Pulmonary Tuberculosis ( TB ) : Chest x-ray show alveolar infiltration at both lung due to mycobacterium tuberculosis infection" • blackday - "Highlighted Chest X-Ray Showing Inflammation or Lung Infection" • manassanant - "Doctor checking chest xray lung scan film of patient in radiology department at hospital." • AkuAku - "Pulmonary Tuberculosis: Both lung infiltrate caused by Mycobacterium tuberculosis infection." • cunaplus - "Doctor diagnosing patient’s health on asthma, lung disease, long COVID-19, coronavirus or bone cancer illness with radiological chest x-ray film for medical healthcare hospital service" • TripleP Studio - " Health care and medical about lungs. respiratory disease, lung cancer, bronchitis, bronchial asthma, tuberculosis, pneumonia, hospital. world no tobacco day. lung disease treatment for hospital."